CRISPR's upcoming trial data and increasing demand for Casgevy drive Evercore's bullish outlook and a higher price target ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports.

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

Citi analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP) stock, reducing the price target to $82 from $89 while maintaining a Buy rating. The stock, which has shown significant ...

CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...